CA
CTMX icon

Clearstead Advisors’s CytomX Therapeutics CTMX Stock Holding History

Clearstead Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Buy
+4
New +$15 ﹤0.01% 3601

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Clearstead Advisors's CTMX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 4 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #3601 among its holdings.

46 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Clearstead Advisors held 4 shares of CytomX Therapeutics worth $15 as of Q2 2026.
  • CytomX Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3601 holding.
  • 46 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.